Stay updated on ABBV-105 in Rheumatoid Arthritis Clinical Trial

Sign up to get notified when there's something new on the ABBV-105 in Rheumatoid Arthritis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ABBV-105 in Rheumatoid Arthritis Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    No significant changes are visible between the two screenshots; the page content and structure appear unchanged.
    Difference
    0.2%
    Check dated 2025-11-03T13:50:40.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    36 days ago
    Change Detected
    Summary
    The page has been updated to include a government-operating-status notice and a new software version (v3.2.0), replacing the previous v3.1.0.
    Difference
    1%
    Check dated 2025-10-06T04:24:09.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    Major change: page now shows Revision: v3.1.0 and removes several drug-safety topics; indicates a content reorganization with updated versioning rather than new substantive information in the deleted areas.
    Difference
    0.2%
    Check dated 2025-09-28T23:58:35.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Revision bumped from v3.0.1 to v3.0.2. The 'Back to Top' link was removed.
    Difference
    0.1%
    Check dated 2025-09-14T18:42:52.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.
    Difference
    0.1%
    Check dated 2025-09-07T13:07:27.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of detailed facility names and locations, as well as new publications related to drug safety and efficacy. Notably, the drug upadacitinib is highlighted, reflecting a focus on treatment options for rheumatoid arthritis.
    Difference
    4%
    Check dated 2025-08-31T04:29:24.000Z thumbnail image

Stay in the know with updates to ABBV-105 in Rheumatoid Arthritis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ABBV-105 in Rheumatoid Arthritis Clinical Trial page.